Rudenko A Iu, Konoplianko T V, Stetsiuk R A
Lik Sprava. 2002(1):52-6.
In a prospective investigation, efficacy and safety of use of valproate (depakine-syrup) was studied in infants presenting with the epileptic convulsive syndrome that was resistant to phenobarbital. The study comprised 26 patients who ranged from 3 months to 1 year old presenting with primary and secondary generalized convulsive epileptic fit. The use of valproate (depakine-syrup) in a medium therapeutic dose (15 +/- 5) mg/kg per day permitted controlling fits in sixteen babies (61.53%) over six weeks; in other three infants (11.53%) the frequency of paroxysms has come to be strikingly decreased, in one infant (3.84%) there has been achieved only partial control of fits, and it is only in 6 babies that the state remained unchanged. In this way, the use of valproate (depakine-syrup) in babies presenting with primary and secondary generalized cerebral seizure resistant to phenobarbital is an effective means of control of seizures with lesser incidence of ill effects recordable than in case of employment of phenobarbital.
在一项前瞻性研究中，对患有对苯巴比妥耐药的癫痫惊厥综合征的婴儿使用丙戊酸盐（德巴金糖浆）的疗效和安全性进行了研究。该研究包括26名年龄在3个月至1岁之间的原发性和继发性全身性惊厥癫痫发作的患者。每天以中等治疗剂量（15±5）mg/kg使用丙戊酸盐（德巴金糖浆），在六周内使16名婴儿（61.53%）的惊厥得到控制；另外三名婴儿（11.53%）的发作频率显著降低，一名婴儿（3.84%）仅实现了部分惊厥控制，只有6名婴儿的病情保持不变。这样，对于患有对苯巴比妥耐药的原发性和继发性全身性脑惊厥的婴儿，使用丙戊酸盐（德巴金糖浆）是控制惊厥的有效手段，与使用苯巴比妥相比，可记录的不良反应发生率更低。
